Tumor Marker Testing Market Report 2026

The tumor marker testing market size has grown strongly in recent years. It will grow from $18.6 billion in 2025 to $20.12 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, wider use of laboratory diagnostics in oncology, expansion of hospital-based cancer testing, availability of established biochemical markers, growth of diagnostic laboratory networks.

The tumor marker testing market size is expected to see strong growth in the next few years. It will grow to $27.23 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to rising demand for early cancer detection, increasing adoption of precision oncology approaches, expansion of companion diagnostics, growing use of biomarkers in therapy selection, advancements in cancer biomarker research. Major trends in the forecast period include increasing adoption of multiplex tumor marker panels, rising use of blood-based cancer diagnostics, growing integration of tumor markers in treatment monitoring, expansion of early cancer screening programs, enhanced focus on personalized oncology care.

The rising prevalence of cancer is expected to drive growth in the tumor marker testing market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread through the blood and lymphatic systems. Its increasing incidence is driven by factors such as aging populations, environmental exposures, lifestyle changes, and improvements in detection and diagnosis. Tumor marker testing supports cancer management by diagnosing the disease, monitoring treatment response, and detecting recurrence through the measurement of substances produced by cancer cells. For example, in October 2025, the UK National Health Service reported 354,820 new cancer diagnoses in 2023 - an average of 972 per day, which is 8,605 more cases than in 2022. This growing cancer prevalence is therefore fueling demand for tumor marker testing.

Leading companies in the tumor marker testing market are focusing on advanced diagnostics, such as molecular testing solutions, to maintain a competitive edge. Molecular testing analyzes genetic material (DNA or RNA) to detect mutations, pathogens, or specific biomarkers at a molecular level. For instance, in April 2024, RGCC International GmbH, a Switzerland-based personalized cancer treatment company, launched Onco-D-clare, a novel cancer detection test. This test allows cancer detection before symptoms appear by combining molecular biology with artificial neural networks. Onco-D-clare isolates peripheral blood mononuclear cells from blood samples and performs comprehensive gene expression analysis across more than 90 genes.

In June 2023, Quest Diagnostics, a US-based clinical laboratory, acquired Haystack Oncology for $300 million. This acquisition strengthens Quest’s cancer diagnostic capabilities by integrating highly sensitive minimal residual disease (MRD) testing technology. It also enhances the provision of personalized and effective cancer care solutions through innovative liquid biopsy technology. Haystack Oncology is a US-based biotechnology company specializing in advanced oncology diagnostics.

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV.

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor marker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the tumor marker testing market by increasing costs of imported reagents, antibodies, diagnostic kits, analyzers, and laboratory instrumentation used in cancer testing workflows. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported assay components, while Asia-Pacific faces higher costs for test kit manufacturing and exports. These tariffs are raising testing costs and affecting laboratory margins. However, they are also encouraging domestic production of diagnostic reagents, regional kit assembly, and investments in local diagnostic manufacturing capabilities.

The tumor marker testing market research report is one of a series of new reports that provides tumor marker testing market statistics, including tumor marker testing industry global market size, regional shares, competitors with a tumor marker testing market share, detailed tumor marker testing market segments, market trends and opportunities, and any further data you may need to thrive in the tumor marker testing industry. This tumor marker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tumor marker testing involves detecting specific substances - often proteins - produced by cancer cells or by the body in response to cancer to identify and monitor tumors. These tests assist in diagnosing cancer, evaluating treatment effectiveness, and detecting recurrence, and are typically performed using blood, urine, or tissue samples.

The main products used in tumor marker testing include biochemical markers, oncogenes, growth factors, hormones, colony-stimulating factors, lymphokines, immunohistochemical stains, and others. Biochemical markers are measurable substances in the body, such as proteins or enzymes, that reflect biological or pathological processes and are commonly used for disease diagnosis and monitoring. Tumor marker testing is conducted through techniques such as screening, imaging, theranostics, and sigmoidoscopy. These tests are applied across various healthcare settings, including hospitals, commercial and private laboratories, physician offices and group practices, cancer clinics, and ambulatory care centers.

The tumor marker testing market consists of revenues earned by entities by providing services such as genetic testing, prostate-specific antigen (PSA) tests, and dehydrogenase (LDH) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor marker testing market also includes sales of test kits, instrumentation, consumables, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.